Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM37ORC)

Drug Name

GNF-PF-826 Drug Info

Synonyms

GNF-Pf-826; AC1M65LM; CHEMBL599946; N-[3-(4-hydroxyanilino)-4-oxonaphthalen-1-ylidene]thiophene-2-sulfonamide; HMS2671P22; MCULE-4006851150

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Sphingosine-1-phosphate receptor 1 (S1PR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Siponimod	DM2R86O	Multiple sclerosis	8A40	Approved	[2]
Fingolimod	DM5JVAN	Multiple sclerosis	8A40	Approved	[3]
Ozanimod	DMT6AM2	Multiple sclerosis	8A40	Approved	[4]
Etrasimod	DMT0A3Y	Ulcerative colitis	DD71	Approved	[5]
Ponesimod	DMEAOYJ	Multiple sclerosis	8A40	Approved	[6]
MT-1303	DMSE9TH	Crohn disease	DD70	Phase 2	[7]
ONO-4641	DMLUM3Y	Rheumatoid arthritis	FA20	Phase 2	[8]
KRP-203	DMOW9X2	Cutaneous lupus erythematosus	EB5Z	Phase 2	[8]
VTX-002	DMZ8Z5A	Ulcerative colitis	DD71	Phase 2	[9]
CBP-307	DM3TH6Y	Ulcerative colitis	DD71	Phase 2	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Nuclear receptor coactivator 3 (NCOA3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GNF-PF-78	DM7SPRJ	Discovery agent	N.A.	Investigative	[1]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Nuclear receptor coactivator 3 (NCOA3)	TT124R0	NCOA3_HUMAN	Inhibitor	[1]
Sphingosine-1-phosphate receptor 1 (S1PR1)	TT9JZCK	S1PR1_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
3	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
4	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
5	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
7	Sphingosine 1-Phosphate Receptor Modulators in Multiple Sclerosis. CNS Drugs. 2015 Jul;29(7):565-75.
8	Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov. 2013 Sep;12(9):688-702.
9	Clinical pipeline report, company report or official report of Ventyx Biosciences
10	Clinical pipeline report, company report or official report of Connect Biopharma